← Leaderboards
James W. Young
Sloan-Kettering Institute For Cancer Res
$11,235,643
Attributed
$11,235,643
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$11,235,643 · 9
By mechanism
P01$4,861,202 · 4
R01$4,315,149 · 2
R21$2,059,292 · 3
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Richard J O'Reilly$17,498,839
- Miguel-Angel Perales$7,415,804
- Howard I Scher$6,446,552
- Trudy Nan Small$1,868,595
- Joan Massague$31,163,003
Others in their field
Top investigators on “Dendritic Cells”
- Barton F Haynes · Duke University$112,608,041
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- James C. Paulson · Scripps Research Institute$41,568,802
- Ulrich H Von Andrian · Harvard Medical School$32,521,007
- Donald L Morton · John Wayne Cancer Institute$29,042,629
Research focus
Dendritic CellsT-LymphocyteNatural Killer CellsMyelogenousBaseImmunityImmune ResponseImmuneMonocyteAntigen PresentationCytokineResponseAntigensLangerhans CellPublic Health Medicine (Field)Malignant NeoplasmsAllogenicGenerationsHematopoietic Stem Cell TransplantationLymphocyteTransplantationCross PresentationLeukemiaInterleukin-15
Grant awards (38)
Distinquishing the Afferent Sensitization of GVHD from GVL/GVT at the Level of H$272,844
P01 · FY2017 · CA · contact PI
Distinquishing the Afferent Sensitization of GVHD from GVL/GVT at the Level of H$305,380
P01 · FY2016 · CA · contact PI
Distinquishing the Afferent Sensitization of GVHD from GVL/GVT at the Level of H$305,380
P01 · FY2015 · CA · contact PI
Distinquishing the Afferent Sensitization of GVHD from GVL/GVT at the Level of H$296,220
P01 · FY2014 · CA · contact PI
Distinquishing the Afferent Sensitization of GVHD from GVL/GVT at the Level of H$543,960
P01 · FY2013 · CA · contact PI
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY$271,531
R01 · FY2012 · CA · contact PI
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC$309,724
P01 · FY2011 · CA · contact PI
CELL THERAPY$280,401
P01 · FY2011 · CA · contact PI
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY$280,350
R01 · FY2011 · CA · contact PI
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC$329,190
P01 · FY2010 · CA · contact PI
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$318,013
R01 · FY2010 · CA · contact PI
CELL THERAPY$272,450
P01 · FY2010 · CA · contact PI
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY$66,505
R01 · FY2010 · CA · contact PI
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC$324,177
P01 · FY2009 · CA · contact PI
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY$321,909
R01 · FY2009 · CA · contact PI
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$318,013
R01 · FY2009 · CA · contact PI
CELL THERAPY$268,137
P01 · FY2009 · CA · contact PI
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$318,013
R01 · FY2008 · CA · contact PI
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC$316,447
P01 · FY2008 · CA · contact PI
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY$314,034
R01 · FY2008 · CA · contact PI
CELL THERAPY$261,581
P01 · FY2008 · CA · contact PI
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$318,013
R01 · FY2007 · CA · contact PI
Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma$314,717
R21 · FY2007 · CA · contact PI
GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY$312,246
R01 · FY2007 · CA · contact PI
HUMAN DENDRITIC CELLS AND THE ONSET OF INNATE AND ADAPTIVE IMMUNITY IN ALLOGENEIC$290,237
P01 · FY2007 · CA · contact PI
CELL THERAPY$239,858
P01 · FY2007 · CA · contact PI
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$329,662
R01 · FY2006 · CA · contact PI
Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma$328,375
R21 · FY2006 · CA · contact PI
Alemtuzumab treatment of steroid-refractory acute GvHD$345,425
R21 · FY2005 · CA
Alemtuzumab treatment of steroid-refractory acute GvHD$345,425
R21 · FY2004 · CA
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$297,040
R01 · FY2004 · CA
Langerhans vs monocyte-derived dendritic cell vaccines$362,675
R21 · FY2003 · CA
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$290,022
R01 · FY2003 · CA
Langerhans vs monocyte-derived dendritic cell vaccines$362,675
R21 · FY2002 · CA
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$283,205
R01 · FY2002 · CA
DENDRITIC CELL/T-CELL INTERACTIONS IN ALLOGENEIC TRANSPLANTATION$0
P01 · FY2001 · CA
TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS$276,593
R01 · FY2000 · CA
DENDRITIC CELL/T-CELL INTERACTIONS IN ALLOGENEIC TRANSPLANTATION$245,216
P01 · FY2000 · CA